The FDA approved giredestrant with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer after specified prior endocrine therapy.
2
The FDA authorized FoundationOne Liquid CDx as a companion diagnostic to identify patients with ESR1 mutations.
3
In the phase 3 evERA trial, median progression-free survival among patients with ESR1-mutated tumors was 10 months with giredestrant plus everolimus and 5.5 months with comparator endocrine therapy pl
4
Objective response rates in patients with ESR1-mutated tumors were 27% with giredestrant plus everolimus and 14% with comparator endocrine therapy plus everolimus; overall survival data were immature.
5
Common adverse reactions included stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea; the prescribing information warns of bradycardia and embryo-fetal toxicity.
Analysis of England’s multicancer early detection screening trial found modest, temporary diagnostic delays in participating regions, adding to concerns about health system effects and the evidence base for population-level blood-based cancer screening.